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Differential effects of 1,25-(OII)2D3 and 22-oxacalcitriol on phosphate
and calcium metabolism. 1 ,25-dihydroxyvitamin D3 has been used with
success in the treatment of secondary hyperparathyroidism associated
with chronic renal failure. However, frequently I ,25-(OH)2D3 induces
hypercalcemia, especially in those patients ingesting large doses of
calcium carbonate, precluding the administration of therapeutic doses
of 1 ,25-(OH)2D3. In addition, control of serum phosphorus is a persis-
tent problem in patients maintained on chronic hemodialysis and
1 ,25-(OH)D treatment can aggravate the hyperphosphatemia. Thus,
ideally an analog of 1,25-(OH)2D3 that can suppress PTH with minor
effects on calcium (Ca) and phosphate (P04) metabolism would be an
ideal tool to control secondary hyperparathyroidism. We have shown
that 22-oxa-l,25-(OH)2D3 (OCT), an analog of l,25-(OH)2D3 with little
calcemic activity, can suppress PTH mRNA in normal rats and in
cultured bovine parathyroid cells with equipotency to I ,25-(OH)2D3. To
further characterize the differential effects of 1 ,25-(OH)2D3 and OCT on
Ca and P04 metabolism we performed several experiments in intact and
parathyroidectomized (PTX) rats. In metabolic studies in four groups of
normal rats I ,25-(OH)2D3 treatment (8 ng/day) significantly increased
the intestinal Ca absorption from 15.2 2.68% to 30.5 2.85% (P <
0.01), while the same dose of OCT had no effect. A dose of 200 ng/day
of OCT increased intestinal Ca absorption similarly to the 8 ng/day dose
of 1,25-(OH)2D3, from 10.6 2.49% to 24.8 2.35%(P< 0.01). Results
for intestinal P04 absorption were similar to those for Ca. Eight nglday
of I ,25-(OH)2D3 increased intestinal P04 absorption from 21.8 1.94 to
32.6 2.70% (P <0.01), while the same dose of OCT had no effect. The
200 ng/day dose of OCT increased intestinal P04 absorption in a manner
comparable to the 8 nglday dose of l,25-(OH)2D3, from 20.3 1.92 to
29.2 1.74% (P < 0.01). Similar patterns were observed for urinary Ca
and phosphorus excretion, To further characterize the bone-resorbing
effects of l,25-(OH)2D3 and OCT. studies were performed in three
groups of PTX rats fed a P04-deficient diet. I ,25-dihydroxyvitamin D3
(200 nglday) increased plasma phosphorus to 6.09 0.26 mgldl as
compared to 2.41 0.33 mg/dI in vehicle-treated animals. On the other
hand, plasma phosphorus increased to only 3.55 0.23 mg/dl in
OCT-treated animals. We conclude that in normal rats OCT is much
less active than 1 ,25-(OH)2D3 in stimulating both intestinal absorption
and urinary excretion of Ca and phosphorus. Also as shown in PTX rats
fed a P04-deficient diet, OCT is much less effective in raising plasma
phosphorus most likely by bone resorption. Thus, OCT, an analog of
1 ,25-(OH)2D3, can suppress PTH without significant changes in plasma
Ca and phosphorus making it an ideal drug for the treatment of
secondary hyperparathyroidism.
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Secondary hyperparathyroidism is a universal complication
in patients with chronic renal failure. Because of its ability to
suppress parathyroid hormone (PTH) [1—5], 1,25-(OH)2D3 has
been used with success in the treatment of secondary hyper-
parathyroidism [6—12]. Its use is often precluded, however, by
the development of hypercalcemia resulting from its potent
action on intestinal calcium (Ca) absorption and bone mineral
mobilization.
Hyperphosphatemia is also a persistent problem in chronic
hemodialysis patients, and can be further aggravated by thera-
peutic use of 1 ,25-(OH)2D3. In addition, the control of phos-
phate (P04) absorption with large doses of calcium carbonate
[13—15], only increases the risk of hypercalcemia from 1,25-
(OH)2D3 therapy.
Thus, ideally an analog of 1,25-(OH)2D3 that can suppress
PTH with minor effects on Ca and P04 metabolism would be an
ideal tool for the control of secondary hyperparathyroidism.
22-Oxacalcitriol (OCT), an analog of 1 ,25-(OH)2D3 with little
calcemic activity, has been shown to be more potent than
1 ,25-(OH)2D3 in its ability to block the proliferation of leukemic
cells [16, 17] and psoriatic fibroblasts [18]. Our laboratory has
shown OCT to be equipotent to 1 ,25-(OH)2D3 in suppressing
both PTH mRNA in normal rats and PTH secretion in cultured
bovine parathyroid cells [19]. These same studies have shown
that administration of up to 200 ng/day of OCT for seven days
did not increase plasma calcium in normal rats. The present
study further compares the effects of 1 ,25-(OH)2D3 and OCT on
calcium homeostasis by examining net calcium absorption and
urinary calcium excretion. We also report for the first time on
the phosphatemic activity of OCT.
Methods
Materials
Powdered normal rat chow, #5001, was obtained from Ral-
ston Purina Inc. (St. Louis, Missouri, USA). The PO4-deficient
diet was obtained from ICN Biomedicals, Inc. (Costa Mesa,
California, USA). Propylene glycol and hydrochloric acid (HC1)
was purchased from Fisher Scientific (St. Louis, Missouri,
USA). 1 ,25-Dihydroxyvitamin D5 was provided by Dr. Milan
Uskokovic (Hoffman La Roche, Nutley, New Jersey, USA),
and 22-oxacalcitriol was supplied by Chugai Pharmaceuticals
Ltd. (Tokyo, Japan).
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Metabolic studies in normal rats
Blood was drawn via the tail from thirty-two normal female
Sprague-Dawley rats weighing from 225 to 250 g for determina-
tion of plasma total Ca and phosphorus. The animals were then
divided into four groups, placed in individual metabolic cages,
and given free access to powdered normal rat chow containing
0.90% Ca and 0.55% P04 and to deionized water. After a seven
day control period with daily collection of urine and feces and
measurement of dietary intake, blood was again drawn, and
treatment begun. Group 1 received daily injections of vehicle,
200 sl of propylene glycol, group 2 received 8 nglday of
1 ,25-(OH)2D3, group 3 was given 8 nglday of OCT, and group 4
received 200 nglday of OCT. A dose of 8 ng/day of 1,25-
(OH)2D3 was chosen because we have found that dose to
effectively suppress PTH without increasing plasma calcium in
normal animals. We chose the same dose of OCT for compar-
ison. We also wanted to evaluate a higher noncalcemic dose of
OCT (200 ng/day) comparable to the dose of l,25-(OH)2D3
which produces significant hypercalcemia. Groups 1, 2 and 3,
underwent two seven-day experimental periods and group 4
underwent one seven-day experimental period. Urine and feces
were again collected to be analyzed for Ca and phosphorus and
daily dietary intake again measured.
Phosphatemic response to 1,25-(OH)2D3 and OCT in PTX
rats
After obtaining a blood sample from the tail for the determi-
nation of plasma phosphorus and total Ca, 23 female Sprague-
Dawley rats weighing from 225 to 250 g were parathyroidecto-
mized (PTX). After overnight fasting, plasma phosphorus and
Ca were again determined. The criterion for a successful PTX
was a post-PTX total Ca value of less than 7.00 mg/dl. The rats
were divided into three groups and received daily intraperito-
neal injections of (1) vehicle (200 p1 of propylene glycol), (2) 200
ng!day of 1,25-(OH)2D3 or (3) 200 nglday OCT for eight days.
Plasma was obtained every 24 to 48 hours via the tail for plasma
total Ca and phosphorus determinations. The rats had free
access to a PO4-deficient diet containing 0.4% Ca and 0.02%
phosphorus and to deionized water.
Analytical determinations
After acidification with HC1, urinary volume was measured,
and each 24-hour urine sample was analyzed for Ca and
phosphorus. Feces for each period were pooled, dried in a
drying oven at 100°C for 24 hours, weighed, and ashed in a Lab
Heat muffle oven (Blue M Corporation, Blue Island, Illinois,
USA) at 700°C for 24 hours. The ash was then dissolved in 5 ml
of concentrated HC1 and analyzed for Ca and phosphorus. Prior
to the studies a sample of each diet was also analyzed for Ca
and phosphorus using this same method. Urinary excretion is
expressed as total Ca or phosphorus excreted in mg per 24
hours. The net amount of intestinal Ca or phosphorus absorbed
is expressed as the % of ingested Ca and phosphorus not
appearing in the feces. Thus, the average daily fecal Ca or
phosphorus is first subtracted from the average daily ingested
Ca or phosphorus to obtain the absolute amount absorbed. That
value is then expressed as a % of the daily ingested Ca or
phosphorus to get the % absorbed.
FIg. 1. The percent of intestinal P04 absorbed per twenty-four hours in
control (•) and experimental () periods in response to vehicle, 8
ng/day of 1,25-(OH)2D3, 8 ng/day of OCT or 200 ng/day of OCT in
normal rats fed a normal diet. Treatment with 8 ng/day of 1 ,25-(OH)2D3
produced a marked increase in the percent of intestinal P04 absorbed,
while the same dose of OCT had no effect. A dose of 200 ng/day of OCT
produced a similar effect to the 8 ng/day dose of 1,25-(OH)2D3. Data
points are expressed as mean SEM. N = 8 for all groups. *D < 0.01
from control.
Total Ca was determined by atomic absorption spectropho-
tometry (Perkin Elmer, Model 1 bOB, Norwalk, Connecticut,
USA). Phosphorus was analyzed using a Multistat 111+ (Instru-
mentation Laboratories, Lexington, Massachusetts, USA).
Statistical analysis
All data are expressed as mean SEM. One-way analysis of
variance (ANOVA) was used for comparisons between groups.
Results
Metabolic studies in normal rats
Dietary intake did not change with treatment in any of the
groups. With 8 ng/day of l,25-(OH)2D3 intake was 16.7 0.83
g/day in the control period and 15.7 0.82 glday in the
experimental period. In control and experimental periods di-
etary intake was 15.5 0.43 and 15.4 0.39 g/day respectively
in the group receiving 8 nglday of OCT and 15.9 0.55 and 15.6
0.44 g/day in the group receiving 200 ng/day of OCT.
The percent of ingested P04 absorbed is shown in Figure 1.
There was no difference among the four groups during the
control period. 1 ,25-Dihydroxyvitamin D3 treatment resulted in
an increase in the percent of P04 absorbed, from 21.8 1.94 to
32.6 2.70% (P <0.01), while the same dose of OCT produced
no change. The 200 ng/day of OCT increased P04 absorption
from 20.3 1.92 to 29.2 1.74% (P < 0.01) and was not
significantly different from the 8 ng/day dose of I ,25-(OH)2D3.
Figure 2 shows similar results for the percent of ingested
calcium absorbed. Treatment with 8 ng/day of 1 ,25-(OH)2D3
increased intestinal Ca absorption from 15.2 2.68 to 30.5
2.85% (P < 0.01), while the same dose of OCT produced no
significant change. Two hundred nanograms per day of OCT
produced an increase in Ca absorption, from 10.6 2.49 to 24.8
2.35% (P < 0.01). This increase was not significantly different
from the 8 nglday dose of 1,25-(OH)2D3.
Figure 3 illustrates the 24-hour urinary phosphorus excretion
in the four groups of animals during control and experimental
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Fig. 2. The percent of intestinal calcium absorbed per twenty-four
hours in control (•) and experimental () periods in response to
vehicle, 8 ng/day of 1,25-(OH)2D3, 8 ng/day of OCT or 200 ng/day of
OCT in normal rats fed a normal diet. Treatment with 8 ng/day of
I ,25-(OH)2D3 produced a marked increase in the percent of intestinal
calcium absorbed, while the same dose of OCT had no effect. A dose of
200 ng/day of OCT produced a similar effect to the 8 nglday dose of
1 ,25-(OH)2D3. Data points are expressed as mean sEai. N = 8 for all
groups. < 0.01 from control.
Fig. 3. The twenty-four hour urinary excretion of phosphorus during
control (U) and experimental () periods in response to vehicle, 8
ng/day of 1,25-(OH)2D3, 8 ng/day of OCT or 200 ng/day of OCT in
normal rats fed a normal diet. Treatment with 8 ng/day of I ,25-(OH)2D3
produced a marked increase in urinary phosphorus excretion, while the
same dose of OCT had no effect. A dose of 200 ng/day of OCT produced
a similar effect to the 8 ng/day dose of 1,25-(OH)2D3. Data points are
expressed as mean SCM. N = 8 for all groups, *p < 0.01 from control.
Fig. 4. The twenty-four hour urinary excretion of calcium during
control (•) and experimental () periods in response to vehicle, 8
ng/day of 1,25-(OH)2D3, 8 ng/day of OCT or 200 ng/day of OCT in
normal rats fed a normal diet. Treatment with 8 nglday of 1 ,25-(OH)2D3
produced a marked increase in urinary calcium excretion, while the
same dose of OCT a lesser effect. A dose of 200 ng/day of OCT
produced a similar effect to the 8 ng/day dose of 1,25-(OH)2D3. Data
points are expressed as mean SEM. N = 8 for all groups. < 0.01
from control.
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Fig. 5. Twenty-four hour urinary phosphorus excretion plotted against
the twenty-four net amount of intestinal phosphorus absorbed for rats
treated with 8 ng/day of OCT (A) or 8 ng/day of 1,25-(OH)2D3 (U).
Significant differences are shown between each group clearly demon-
strating a more potent effect of 1 ,25-(OH)2D, on phosphate balance.
Data points are expressed as mean SCM. N = 8 for all groups.
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periods. There was no difference in urinary phosphorus excre-
tion in the four groups of animals during the control period.
1 ,25-Dihydroxyvitamin D3 treatment increased urinary phos-
phorus from a control value of 9.52 1.43 to 13.83 0.96 mg/24
hr (P < 0.05), while the same dose of OCT had no effect. The
200 ng/day dose of OCT increased urinary phosphorus from
7.85 1.15 to 16.2 1.57 (P < 0.001). This increase was not
significantly different from the 8 ng/day dose of 1 ,25-(OH)2D3.
Twenty-four-hour urinary Ca excretion (Ua) in the four
groups of animals during control and experimental periods is
shown in Figure 4. After l,25-(OH)2D3 treatment (8 nglday),
urinary Ca increased from a control value of 4.45 0.83 to 16.7
1.31 mg/24 hr (P < 0.001). Urinary Ca also increased in the
group receiving 8 ng/day of OCT, from 3.34 0.36 to 11.3
1.10 mg/24 hr (P < 0.001). Two hundred nanograms per day of
OCT caused a greater increase in Ua, from 5.24 0.68 to 14.7
1.37 mg/24 hr (P < 0.001). The 8 ng/day dose of OCT
produced significantly less calciuria than did the same dose of
1 ,25-(OH)2D3 (P < 0.01) while there was no significant differ-
ence between the 8 ng/day dose of 1 ,25-(OH)2D3 and the 200
nglday dose of OCT.
Urinary creatinine (Ur) excretion did not change with treat-
ment in any of the groups. With 8 ng/day of 1 ,25-(OH)2D3 U.
was 9.44 0.45 in the control period and 9.33 0.27 mg/day
during the experimental period. In control and experimental
periods Ur was 8.58 0.21 and 8.96 0.34 mg/24 hr,
respectively, in the group receiving 8 ng/day of OCT and 8.41
0.46 and 8.79 0.44 mg/24 hr in the group receiving 200 ng/24
hr of OCT.
Figure 5 compares the urinary phosphorus excretion plotted
against the net intestinal phosphorus absorption for rats receiv-
ing 8 ng/day of OCT to those receiving 8 nglday of 1,25-
(OH)2D3. Significant differences are shown between each group
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Fig. 6. Twenty-four hour urinary calcium excretion plotted against the
twenty-four net amount of intestinal calcium absorbed for rats treated
with 8 ng/day of OCT (A) or 8 ng/day of 1,25-(OH)2D3 (•). Significant
differences are shown between each group clearly demonstrating a
more potent effect of 1 ,25-(OH)2D3 on calcium balance. Data points are
expressed as mean SEM. N = 8 for all groups.
clearly demonstrating a more potent effect of 1,25-(OH)2D3 on
phosphate balance.
Figure 6 compares the urinary calcium excretion plotted
against the net intestinal calcium absorption for rats receiving 8
ng!day of OCT to those receiving 8 ng/day of 1 ,25-(OH)2D3.
Again, there is a significant difference between the two groups
clearly demonstrating a more potent effect of 1,25-(OH)2D3 on
calcium balance.
Plasma calcium in all groups of rats was not affected by
treatment with 1,25-(OH)2D3 or OCT (data not shown).
Phosphatemic response to 1 ,25-(OH)2D3 and OCT in PTX
rats
The effect of vehicle, 1 ,25-(OH)2D3, or OCT treatment on
plasma phosphorus in PTX rats fed a P04-deficient diet is
shown in Figure 7. As expected, plasma phosphorus rose
immediately after PTX, but then dropped in the absence of
dietary phosphorus. Mter eight days of treatment, plasma
phosphorus decreased from a pre-PTX value or 5.44 0.23
mg/dl to 2.41 0.33 mg/dl in vehicle treated animals, but
increased from 5.54 0.30 mg/dl to 6.09 0.26 mgldl (P <
0.001) in rats receiving 1 ,25-(OH)2D3. Plasma phosphorus levels
decreased to 3.55 0.23 mgldl (P < 0.01) from a pre-PTX value
of 5.59 0.17 mg/dl in OCT treated rats during the same period.
Parathyroidectomized rats receiving 1 ,25-(OH)2D3 experienced
some weight loss by the end of the study compared to the other
two groups, weighing 185.3 3.34 g versus 244.9 4.89 g for
controls animals and 239.4 2.58 g for the OCT treated group.
Discussion
Decreased renal function is characterized by changes in
mineral homeostasis, with secondary hyperparathyroidism ap-
pearing even in the early stages of renal insufficiency leading to
the development of renal osteodystrophy [20—22]. Both low
levels of 1 ,25-(OH)2D3 and P04 retention are responsible for the
development of secondary hyperparathyroidism. Phosphate
retention not only promotes hypocalcemia, but also inhibits
renal 1 a-hydroxylase further decreasing 1 ,25-(OH)2D3 [23]. At
all stages of renal failure adequate control of P04 metabolism is
essential in the control of secondary hyperparathyroidism. In
mild to moderate renal failure, PTH is elevated and 1,25-
(OH)2D3, although usually normal [24] to low normal [25], is
inappropriately low for the elevated PTH levels. Although
serum phosphorus is usually normal at this stage, P04 restric-
tion can improve secondary hyperparathyroidism. Decreased
P04 intake increases I ,25-(OH)2D3 levels which in turn de-
crease PTH [26, 27], by directly suppressing PTH gene tran-
scription [4] and by increasing intestinal calcium absorption. In
later stages of renal failure the extent of hyperparathyroidism
and 1 ,25-(OH)2D3 deficiency increases, and P04 restriction has
little effect on 1 ,25-(OH)2D3 levels [28, 29], presumably due to
the decreased renal mass available for 1 ,25-(OH)2D3 synthesis.
Phosphate control at this point is still crucial in treating sec-
ondary hyperparathyroidism, since severe hyperphosphatemia
can lead to a drop in plasma Ca, further stimulating PTH
secretion [30]. In addition, Lopez-Hilker et al showed that P04
restriction can improve secondary hyperparathyroidism inde-
pendently of plasma ionized calcium or I ,25-(OH)2D3 levels
[31].
1,25-Dihydroxyvitamin D3 can have a marked effect on
plasma phosphorus by its phosphatemic action on both intestine
and bone. We have shown in the present metabolic studies
using normal rats that the effect of OCT on intestinal P04
absorption is a fraction of that of 1 ,25-(OH)2D3. While a dose of
8 ng/day of 1,25-(OH)2D3 produced a significant increase in the
intestinal absorption of P04, the same dose of OCT had no
effect. A dose of OCT approximately 25 times that of 1,25-
(OH)2D3 produced a similar increase. At this point we cannot
precisely determine the comparable potency of these two
compounds since we have not performed studies using inter-
mediate doses of OCT between 8 and 200 ng. The exact dose
relationship effect between the two compounds is not part of
this study and requires further investigation. As with intestinal
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Fig. 7. Phosphatemic response to vehicle (• —•; N = 8), or 200
ng/day of 1,25-(OH)2D3 (U — U; N = 7) or OCT (A —A; N = 8) in PTX
rats fed a P04.deficient diet. Treatment with 1 ,25-(OH)2D3 produced a
marked increase in plasma phosphorus, however, the effect of OCT was
less pronounced indicating a decreased effect on bone resorption. Data
points are expressed as mean SEM.
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absorption, OCT also had less of an effect on urinary phospho-
i-us excretion compared to 1,25-(OH)2D3. Eight nanograms per
day of I ,25-(OH)2D3 produced marked phosphaturia, whereas
no increase in urinary phosphorus was apparent with the same
dose of OCT. Also, l,25-(OH)2D3 treatment in PTX rats fed a
P04-deficient diet produced a dramatic increase in plasma
phosphorus, most likely caused by a phosphatemic response by
bone to l,25-(OH)2D3. By comparison, the response to OCT
was minimal. Since 1 ,25-(OH)2D3 treated animals weighed less
at the end of the study, a contribution of phosphorus by tissues
other than bone cannot be ruled out. Both of these studies
demonstrate that the effect of OCT on intestinal P04 absorp-
tion, and most likely bone P04 mobilization is much lower than
that of l,25-(OH)2D3.
Although in the 1 ,25-(OH)2D3-treated group one might expect
a change in plasma calcium if there is an increase in both the
intestinal absorption of calcium and in the urinary calcium
excretion, precise adaptations may occur which offset a change
in plasma calcium. For instance, if a diet high in salt is ingested,
urinary sodium excretion increases while a change in plasma
sodium is rarely detected. Also small changes in plasma calcium
may go undetected even if more frequent measurements of
plasma ionized calcium are made.
Although l,25-(OH)2D3 has been shown to be a potent
therapeutic agent in the treatment of secondary hyperparathy-
roidism, the risk of hypercalcemia, especially in those patients
ingesting large doses of calcium carbonate, can limit its effec-
tive use. In previous studies from our laboratory using PTX rats
fed a Ca-deficient diet, we demonstrated that the effect of OCT
on bone Ca mobilization is minimal compared to that of
l,25-(OH)2D3 [32]. In the present metabolic studies we show
that the effect of OCT on intestinal Ca absorption is also
minimal compared to that of I ,25-(OH)2D3. A dose of 8 ng/day
of 1 ,25-(OH)2D3 produced a significant increase in intestinal
calcium absorption; the same dose of OCT had no effect. This
dose of OCT is important because we have shown suppression
of pre-pro-PTH messenger RNA in uremic rats with no increase
in plasma calcium [33]. A dose of OCT approximately 25 times
that of 1 ,25-(OH)2D3 produced a similar increase although there
was no accompanying increase in plasma calcium. The calciuria
produced by OCT was also substantially less than that of
1 ,25-(OH)2D3. This study and the previous one in PTX rats fed
a Ca-deficient diet [32] demonstrate that the effect of OCT on
intestinal Ca absorption and bone Ca mobilization is minimal
relative to 1 ,25-(OH)2D5.
It remains unclear why OCT would be more potent than
1 ,25-(OH)2D3 in its ability to differentiate leukemia cells and
psoriatic fibroblasts and equipotent in suppressing PTH, yet
have a fraction of the effect of 1 ,25-(OH)2D3 on P04 and Ca
metabolism. 22-Oxacalcitriol however, binds less avidly to the
vitamin D binding protein (DBP) than l,25-(OH)2D3 [34, 35].
One important function of DBP is to prolong the half life of
vitamin D metabolites in circulation. Dusso et a! have shown
that OCT is cleared more rapidly from circulation than 1,25-
(OH)2D3 [36]. The shorter time of exposure of OCT to the target
tissue could explain the decreased activity of OCT in bone and
intestine, but not the greater or equal potency in cell differen-
tiation and PTH suppression. Recently, Zhou, Nemere and
Norman [37] studied the effect of several analogs of 1,25-
(OH)2D3 on the rapid stimulation of intestinal calcium absorp-
tion (transcaltachia). They demonstrated that different struc-
tural features are essential for initiating the transcaltachic
response as contrasted with binding to the classic nuclear
receptor. Their results indicate that the membrane components
that respond to analogs of I ,25-(OH)2D3 with activation of Ca2
channels have a different ligand specificity than the classic
nuclear receptor. Another striking property of OCT is its
inability to mimic 1 ,25-(OH)2D3 in increasing intracellular cal-
cium in ROS 17/2.8 cells and HL-60 cells [38]. It is not known
ii this is a general property of OCT or whether it can account for
the low activity in the intestine and bone. Clearly, further
clarification is needed on the mechanism(s) for the difference in
response to OCT in various target tissues compared to 1,25-
(OH)2D3.
In conclusion, OCT is much less active than 1 ,25-(OH)2D3 in
stimulating both intestinal absorption and urinary excretion of
Ca and phosphorus. Also as shown in PTX rats fed a low
phosphorus diet, OCT is much less effective in raising plasma
phosphorus most likely caused by a decreased action on bone
resorption. Thus, OCT, an analog of 1,25-(OH)2D3, can sup-
press PTH without significant changes in plasma Ca and phos-
phorus making it an ideal drug for the treatment of secondary
hyperparathyroidism.
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